Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$29.86 USD
+0.21 (0.71%)
Updated May 9, 2024 04:00 PM ET
After-Market: $29.85 -0.01 (-0.03%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth C Momentum B VGM
Brokerage Reports
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 681 - 700 ( 717 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
EMA Concerns Regarding DepoCyte Manufacturing Not Material, In Our View
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
July Symphony Health Data for EXPAREL; Reiterate OUTPERFORM and $18 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q2 EXPAREL Sales Beat as Launch Off to Very Promising Start; Reiterate OUTPERFORM and $18 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
August and Remaining 2012 Catalysts for Emerging Pharmaceuticals.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
June Wolters Kluwer Data for EXPAREL. Reiterate OUTPERFORM and $18 Fair Value.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
May Wolters Kluwer Data for EXPAREL Suggests Solid Second Month of Sales
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
New Health Economics Data Provides Compelling Marketing Tool for Exparel, In Our View
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Movie Rental and Exhibitor Biweekly Newsletter-May 21 - June 3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
April Wolters Kluwer Data for EXPAREL; Reiterate OUTPERFORM and $15 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q1 Financials: We Believe April EXPAREL Sales Suggest Solid Start to Launch. Reiterate OUTPERFORM and $15 FV.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
We Estimate Financing Extends Cash Runway Into Potential Profitability - Reiterate OUTPERFORM, FV Lowered to $15
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
EXPAREL Now Commercially Available-We Believe Groundwork Laid for a Successful aunch-Reiterate
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of April 1
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Emerging Pharmaceuticals -Q2 2012 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q4 Financials Uneventful. We See a Robust EXPAREL Launch the Week of April 9. Reiterate OUTPERFORM.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
3-Month Delay in EXPAREL Launch Results in Only Slight Revenue Impact But Provides Additional Time for Manufacturing and Pre-Launch Activities.
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
LIFE SCIENCES: 2012 Life Sciences and Healthcare Preview: Macro and Sector Trends; Catalysts; Top Picks
Provider: WEDBUSH SECURITIES INC.
Analyst: JAMES S